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A B S T R A C T
Engineered transcription factors (TF) have expanded our ability to modulate gene expression and hold great
promise as bio-therapeutics. The first-generation TF, based on Zinc Fingers or Transcription-Activator-like
Effectors (TALE), required complex and time-consuming assembly protocols, and were indeed replaced in recent
years by the CRISPR activation (CRISPRa) technology. Here, with coagulation F7/F8 gene promoters as models,
we exploited a CRISPRa system based on deactivated (d)Cas9, fused with a transcriptional activator (VPR),
which is driven to its target by a single guide (sg)RNA.
Reporter gene assays in hepatoma cells identified a sgRNA (sgRNAF7.5) triggering a ~35-fold increase in the
activity of F7 promoter, either wild-type, or defective due to the c.-61T>G mutation. The effect was higher
(~15-fold) than that of an engineered TALE-TF (TF4) targeting the same promoter region. Noticeably, when
challenged on the endogenous F7 gene, the dCas9-VPR/sgRNAF7.5 combination was more efficient (~6.5-fold) in
promoting factor VII (FVII) protein secretion/activity than TF4 (~3.8-fold). The approach was translated to the
promoter of F8, whose reduced expression causes hemophilia A. Reporter gene assays in hepatic and endothelial
cells identified sgRNAs that, respectively, appreciably increased F8 promoter activity (sgRNAF8.1, ~8-fold and 3-
fold; sgRNAF8.2, ~19-fold and 2-fold) with synergistic effects (~38-fold and 2.7-fold). Since modest increases in
F7/F8 expression would ameliorate patients' phenotype, the CRISPRa-mediated transactivation extent might
approach the low therapeutic threshold.
Through this pioneer study we demonstrated that the CRISPRa system is easily tailorable to increase ex-
pression, or rescue disease-causing mutations, of different promoters, with potential intriguing implications for
human disease models.
1. Introduction
In the last decade the modulation of gene transcription has attracted
attention for therapeutic purposes in human disease, either by gene
activation/repression or modification of the chromatin architecture. So
far the most used approaches have been based on the manipulation of
Zinc-fingers (ZFs) [1] or Transcription activator-like effectors (TALEs)
[2] fused to transcriptional regulators.
ZFs typically occur in tandem arrays, and many transcription factors
have three or more fingers working together to recognize specific tar-
gets on DNA. The ZFs activators have been successfully exploited to
enhance endogenous expression of different human genes, including the
erythropoietin [3], ERBB2 [4] and EGF2 [5] genes.
TALE proteins have a complex DNA-binding domain, which is
composed of a variable number of tandem repeats differentiated only
for residues at positions 12–13 of each monomer (repeat variable di-
residue, RVD). The RVD dictates the specificity of recognition of the
target DNA sequence [6,7]. TALE-based transcription activators (TALE-
TF) have been exploited to drive the expression of different genes such
as Oct4 [8,9], Frataxin [2] and for cellular reprogramming [10].
However, despite their efficacy, the exploitation of ZFs and TALE
tools requires a tedious and time-consuming protocols.
In this context, the advent of the technology based on CRISPR, so far
extensively exploited for genome editing [11], has opened new per-
spectives. The CRISPR activation (CRISPRa) system is composed of a
deactivated CRISPR-associated protein 9 (dCas9), obtained by means of
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two missense mutations in the RuvC and HNH domains, fused with a
transcriptional activator, and a single guide RNA (sgRNA) [12]. Since
the first usage of this technology many steps have been done using
different kinds of activators. First-generation activators were directly
fused to the dCas9, while second-generation consist of activators ar-
ranged in a scaffold (SAM, SunTag) [13,14], exerting a synergistic ef-
fect, or of a tripartite activator composed by VP64, p65 and Rta (named
as VPR) [15].
These features of the CRISPRa system, easily driven to the target by
appropriately designed sgRNAs, makes it easy to be designed and rea-
lized, as well as highly versatile. However, a very few studies have been
performed on the manipulation of gene expression by CRISPRa [16],
particularly on the transactivation of defective promoters or of poorly
expressed genes, which prevents the assessment and comparison with
the previous approaches. In this field, we have recently demonstrated
that a properly designed TALE-TF was able to rescue F7 promoter ac-
tivity affected by mutations lowering coagulation factor VII (FVII) ex-
pression and associated with severe deficiency [17].
Here, by exploiting the CRISPRa system in the model of coagulation,
we modulated the expression of normal and mutated F7 promoter.
Noticeably, we extended the application to F8, with a higher degree of
complexity and associated with the most frequent bleeding disorder
hemophilia A, and which is poorly expressed. We demonstrated that the
CRISPRa is easily tailorable on both promoter models and can guar-
antee a stronger effect than that of TALE TF.
2. Materials and methods
2.1. Expression vectors
The pF7wt and the pF7-61G vectors were obtained as previously de-
scribed [17].
To create the pF8 reporter construct (pF8), the F8 promoter region
(1175 bp) was PCR amplified with primers 5’AAACTCGAGAAATAAAT
GAATAAATGCCA3’ and 5’AAAAAGCTTCATGACTTATTGCTACAAAT3’
and cloned upstream of the firefly luciferase sequence into the pGL3
Basic Vector (Promega, Madison, WI, USA) [17].
The sgRNAs were designed with the ZiFit web tool (http://zifit.
partners.org/ZiFiT/) by entering the 92 bp of the proximal region of the
F7 promoter or 333 bp of the F8 promoter, and scanning for the
Streptococcus pyogenes PAM sequence (NGG) both in sense and antisense
strands. Potential off-targets were predicted through the Cas OFFinder
tool (http://www.rgenome.net). To generate sgRNAs expression cas-
sette, the pMLM3636 plasmid was digested with BsmBI and cloned with
a pair of annealed oligonucleotides (Supplementary Table 1). pSP-
dCas9-VPR was a gift from George Church (Addgene plasmid #63798)
and pMLM3636 was a gift from Keith Joung (Addgene plasmid
#43860).
2.2. Transfection and evaluation of luciferase and FVII expression
The human hepatoma HepG2 and Huh-7 cells were transfected in
12-well plates as described [17]. For reporter gene assays, cells were
transfected with 1 μg of pF7/pF8 plasmids and i) 0.5 μg of pdCas9-VPR
and 0.25 μg of pMLM3636 or ii) 0.5μg of pTF4. To normalize for
transfection efficiency, cells were co-transfected with 100ng of the
pRluc control plasmid (Promega) expressing the Renilla luciferase. To
evaluate the endogenous FVII expression, cells were transfected in 6-
well plates with 1 μg of pdCas9-VPR and 0.5 μg of pMLM3636 or 1 μg of
pTF4.
Forty-eight hours post-transfection, luciferase activity was assessed
on cell lysates by the Dual-Luciferase assay (Promega) according to the
manufacturer's protocol. FVII-containing medium was collected to
measure FVII secreted protein and activity levels by ELISA and
fluorogenic assays monitoring the generation of activated factor X
(FXa), respectively [18].
Fig. 1. Activity of the CRISPRa ap-
proach on F7 promoter in reporter
assays.
A) Schematic representation of the pSP-
dCas9-VPR (upper scheme) and sgRNA
backbone (MLM3636, lower scheme).
dCas9-VPR is composed of a deacti-
vated (d)Cas9 from Streptococcus pyo-
genes (HNH and RuvC inactivated do-
mains) fused with a VPR domain, which
consists of three different transcription
activators (VP64, p65 and Rta) re-
cruiting the transcriptional machinery.
The single guide (sg)RNAs are under
the control of the human U6 promoter.
The scaffold sequence is necessary for
the recruitment of Cas9.
B) Representation of the reporter pF7
constructs, which include the proximal
F7 promoter region (520 bp) driving
the expression of the firefly luciferase.
The localization of the five sgRNAs
(sgRNAs F7.1–5) is reported above/
below the scheme. The mutated HNF4
binding sequence (−61 T > G) is also
indicated.
C) Transactivation activity of the de-
signed sgRNAs on the wild-type and
mutant -61G promoters. Histograms
report the fold increase of the luciferase
activity over the pF7wt. The results are
expressed as mean ± standard devia-
tion from three independent experi-
ments conducted in HepG2 cells.
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2.3. Data analysis
The specific parameter lag time in functional assays was obtained by
extrapolating the first derivative of relative fluorescence units (RFU) as
a function of time (seconds) [19]. Statistical differences were evaluated
by the t-test.
3. Results and discussion
To evaluate the CRISPRa transactivation potential and to provide
with an informative comparison with the TALE-TF approach, we have
chosen as model the F7 gene promoter either wild-type or bearing the
-61 T > G mutation, remarkably affecting the promoter activity and
leading to severe FVII deficiency [20,21].
To this purpose, we chose a second-generation dCas9 fused with the
tripartite transcription activator VPR (Fig. 1A), which has been de-
monstrated to be highly efficient [15,22].
3.1. Screening and identification of sgRNAs driving F7 promoter
transactivation in cultured cells
Computational analysis led us to design a panel of five sgRNAs
targeting the F7 promoter in the region from −89 to +1, in particular
that falling between the HNF4 binding motif and the transcription start
site (sgRNAs F7.1–4) (Fig. 1B). An additional sgRNA (sgRNAF7.5) was
designed to bind the sequence between SP1 and HNF4 binding sites, a
region overlapping with that recognized by the most active TALE-TF
(TF4) previously identified by us [17].
Reporter gene assays in HepG2 cells transfected with dCas9-VPR
and the sgRNA-expressing vector demonstrated that all sgRNAs induced
an increase of transcriptional activity ranging from 2-fold (sgRNAF7.2)
to over 40-fold with the other sgRNAs in the wild-type context
(Fig. 1C). In the mutated -61 T > G context the CRISPRa system re-
sulted in a promoter activity overlapping with that of the wild-type
promoter in the same experimental conditions. As a matter of fact, as
compared to untreated cells, the luciferase activity in the presence of
the sgRNAF7.5 was increased over 45-fold.
Altogether these studies demonstrated the transactivation activity of
the CRISPRa approach on defective F7 promoter and identified the
sgRNAF7.5 as the most active.
3.2. Comparison between CRISPRa and TALE-TF transactivation activities
in reporter gene assays
The observation that the selected sgRNAF7.5 targets the region be-
tween the SP1 and HNF4 binding sites, as the most active TF4 (Fig. 2A)
that we previously characterized [17], prompted us to directly compare
their activity in the same experimental set-up. As shown in Fig. 2B, the
co-expression of dCas9-VPR with the sgRNAF7.5 increased F7 promoter
activity, either wild-type or mutated, of ~30-fold whereas the effect of
the TF4 was approximately ~18-fold, taken the activity of the un-
treated cells expressing the wild-type construct as 1. Noticeably, the
dCas9-based approach resulted in a transactivation efficiency sig-
nificantly higher than that promoted by TF4 in both wild-type
(p=0.0424) and mutated (p=0.0123) F7 contexts. This experimental
evidence could be explained by the accessibility of the whole region of
the F7 promoter to natural transcription factors, as suggested by ana-
lysis of ChIPseq data (ENCODE database, https://www.encodeproject.
org/), which points toward favorable interactions of both sgRNAF7.5
and TF4 to the sequence between the SP1 and HNF4 motifs (Supple-
mentary Fig. 1).
Although it is difficult to assess the molar amount of the different
molecular components acting in the two systems, these data point to-
ward an increased transactivation capacity of the CRISPRa approach.
This finding might be in part attributable to the structural differences
between CRISPRa and TALE-TF, the former exploiting the VPR-fused
dCas9 [15] that is known to be more efficient than the dCas9 fused with
the VP64 single domain typical of TALE-TF.
3.3. Comparison of CRISPRa and TF4 activity on endogenous FVII protein
expression in human hepatoma cells
To assess the transactivation capacity in the chromatin context we
challenged the dCas9-VPR/sgRNAF7.5 complex and TF4 on the en-
dogenous F7 gene expression in HepG2 cells. We therefore assessed
their impact on secreted FVII protein levels, and particularly on the
activity through very sensitive fluorogenic functional assays, optimized
to detect very low activity levels, measuring the ability of FVII to ac-
tivate its physiologic substrate factor X [23]. As shown in Fig. 3A,
supplementation of FVII-deficient plasma with medium from HepG2
cells transfected with the dCas9-VPR/sgRNAF7.5 combination resulted
in an appreciable shortening of lag times (from 1400 s to 867 s) as
compared with medium from untransfected cells, to indicate an in-
creased FVII activity. Noticeably, the impact on lag times was stronger
than that of medium from cells transfected with TF4 (1050 s). When
extrapolated by comparison with serial dilutions of pooled normal
plasma, the activity upon treatment with dCas9-VPR/sgRNAF7.5 or TF4
resulted to be increased of 6.5 ± 0.49 or 3.8 ± 0.53 fold over the
negative control, respectively (Fig. 3B). It is worth noting that the lag
time, a key time parameter indicating when the generation of FXa be-
gins, is dictated by FVII activity levels [24], thus being a clear hallmark
of FVII-dependent improvement of the activity measured in plasma.
These data in cellular models further support the greater transacti-
vation potential of the CRISPRa approach toward the TALE-TF.
Fig. 2. Comparison of transactivation activity between sgRNAF7.5 and TF4.
A) Schematic representation of the recognized sequences by sgRNAF7.5 and TF4
in the region between SP1 and HNF4 transcription binding sites.
B) Co-expression in HepG2 cells of the reporter plasmids pF7wt and pF7-61G
alone or in the presence of TF4 and dCas9/sgRNAF7.5. Histograms report the
fold increase of relative luciferase activity over that of the pF7wt alone. Results
are expressed as mean ± standard deviation from three independent experi-
ments.
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3.4. Tailoring the CRISPRa approach for coagulation F8 promoter
To further challenge the CRISPRa system, and assess its versatility,
we tested it on the F8 gene promoter driving the expression of coagu-
lation factor VIII (FVIII), a key cofactor whose reduced levels lead to
hemophilia A [25]. Although the frequency of promoter mutations in
hemophilia A is relatively lower (0.2–0.3%;http://www.factorviii-db.
org/) [26,27] than in hemophilia B (~2.5%) [28], the F8 gene as model
exemplifies the potential of the CRISPRa-mediated approach due to the
higher complexity of its promoter (Fig. 4A) as compared with that of F7
(Fig. 2A).
We therefore designed a panel of five sgRNAs to cover a region of
~300 bp upstream of the transcription start site. Moreover, we designed
a single sgRNA (sgRNAF8.2) to partially target the proximal C/EBPβ
binding motif (Fig. 4A), known to play a crucial role on F8 gene ex-
pression [29].
In reporter assays in which the expression of the firefly luciferase
was driven by the whole F8 proximal promoter region (1175 bp) [30]
we detected a very low F8 promoter activity (~2 fold) as compared
with the negative control (pBasic) (Fig. 4B, inset), which is consistent
with the weakness of the F8 promoter. The screening for transactivation
activity with the dCas9-VPR and the different sgRNAs revealed a vari-
able increase of luciferase levels ranging from 4- (sgRNAF8.4) to 20-fold
with the sgRNAF8.2 (Fig. 4B), which partially targets the C/EBPβ
binding motif.
Prompted by previous studies demonstrating that two or more
sgRNAs can magnify the transactivation effect [11,12] we tested the
sgRNAF8 variants in combination. As shown in Fig. 4C, each combina-
tion led to an improved activity over the single sgRNAF8, with the
highest effect (~40 fold) obtained with the combination of sgRNAsF8.2,
the most active when challenged alone, with sgRNAF8.1.
To strengthen this finding we challenged the CRISPRa approach in
endothelial EA.hy926 cells, which better resembles the physiological
context for FVIII. In this setting, among all the gRNAs tested, the
sgRNAF8.1 (3.2-fold) and sgRNAF8.2 (2-fold) showed the highest trans-
activation activity of F8 promoter. In particular, when used in combi-
nation, the two sgRNAs resulted in the most significant fold change
(2.7) difference (p < 0.0001) in comparison with the dCas-VPR alone
(Fig. 5), as we observed in hepatic cells. The differential effect of
sgRNAF8.1 and sgRNAF8.2 in comparison with that observed in hepatic
cells could be attributable to the very low transfection efficiency of
EA.hy926 cells [31].
Overall, these data, albeit on the artificial context of a reporter
construct, demonstrate that the CRISPRa can be tailored on F8 gene and
identified, in two different cell models, the sgRNAF8.1 and sgRNAF8.2,
alone or in combination, as those being able to recruit the dCas9-VPR
component and remarkably increase F8 promoter activity. It is worth to
note that the CRISPRa system could be extended also to those missense
mutations exerting a combined impact on splicing and protein bio-
synthesis/activity [32], which would benefit from enhanced promoter
activation.
4. Conclusions
Overall, in this pioneer study using F7 and F8 as paradigmatic
models for coagulation genes, we demonstrated that the CRISPRa
system is highly versatile and can be adapted to gene promoters with
different degree of complexity to increase physiologic expression or to
Fig. 3. Transactivation activity on the endogenous F7 gene in HepG2 cells.
Activated FX (FXa) generation activity in FVII-deficient plasma supplemented with medium from HepG2 cells before (−, untreated) or after transactivation with
either TF4 or dCas9/sgRNAF7.5.
A) Schematic representation of the workflow from transient transfection to activity assays performed to assess the FXa generation activity of FVII-containing medium
after transactivation.
TF, tissue factor; PL, phospholipids; FX, factor X, FXa, activated factor X.
B) Representative calibration curve prepared with serial dilutions (indicated as %) of pooled normal plasma showing the shortening of lag times as a function of
increasing FVII protein amounts secreted in medium after dCas9/sgRNAF7.5- or TF4-mediated transactivation of endogenous F7.
Inset. Activity curves obtained by supplementation of FVII-deficient plasma with FVII-containing or mock medium. Colored arrows indicate the time points used to
extrapolate lag times.
C) Histograms representing the fold increase after transactivation of endogenous F7 expression with TF4 or dCas9/sgRNAF7.5 relatively to untransfected cells (−).
Results are reported as fold increase over endogenous FVII from untreated cells (mean ± standard deviation from three independent experiments).
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rescue promoter mutations associated with human disease. However,
the very low expression profile of FVIII in hepatic cells and the poor
transfection efficiency of endothelial cells hampered the proper
evaluation of the impact on secreted FVIII levels. In this view, although
we are aware of the limit of our study in the use of hepatic cells,
physiological for FVII but not for FVIII, the observed transactivation
should be considered in light of the capacity of the CRISPRa system to
act on both F7 and F8 promoters. Noticeably, the extent of the im-
provements obtained through the identified sgRNAs, if cautiously
translated into patients, might approach the low therapeutic threshold
for FVII deficiency and hemophilia A [33,34], in which, at variance
from the majority of human disorders, even a modest increase in FVII or
FVIII levels would ameliorate the clinical phenotype.
Notwithstanding, these data encourage further studies aimed at
assessing the therapeutic potential and the safety profile of this ap-
proach, which could be extended to several disease genes.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbagrm.2019.04.002.
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Fig. 4. Tailoring of the CRISPRa system on F8 promoter transactivation.
A) Schematic representation of the proximal F8 promoter region cloned upstream of the luciferase-encoding sequence. Designed sgRNAs are shown above/below the
predicted target region.
B,C) Promoter activity of the F8 reporter vector after transfection with single (B) or combinations (C) of sgRNAs targeting the region shown in A.
Histograms report the fold increase of relative luciferase activity over that of F8 alone. The dCas9-VPR, devoid of the DNA-binding component, and pBasic (B, inset),
were used as negative controls.
Results are expressed as mean ± standard deviation from three independent experiments.
*, p < 0.05; **, p < 0.005; ***, p < 0.0005; ****, p < 0.0001; ns, not significant.
Fig. 5. F8 promoter transactivation in endothelial EA.hy926 cells.
Promoter activity of the F8 reporter vector after transfection with sgRNAs,
targeting the region shown in Fig. 4A, represented as fold increase of relative
luciferase activity over that of F8 alone.
Results are expressed as mean ± standard deviation from at least three in-
dependent experiments.
*, p < 0.05; **, p < 0.005; ***, p < 0.0005; ****, p < 0.0001; ns, not sig-
nificant.
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